FlowDesk — News

Headlines

Bullish tone

Bearish tone

Symbol-tagged

News sentiment over time

Daily average lexicon sentiment across 226 scored headlines over the last 8 days. For market-wide mood (VIX, breadth, regime), see Markets. For the learned model that predicts forward return from a headline, see Headline Forecast Model.

Yahoo2026-09-09 21:48:01

Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)?

On August 27, AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) scored a shared clinical victory. Positive high-level results from the Phase III CROSSING trial showed that their co-developed severe asthma drug, TEZSPIRE, achieved statistically significant and clinically meaningful improvements across both co-primary endpoints, histologic remission and the frequency/severity of dysphagia, and all key secondary endpoints […]

AMGN

Yahoo2026-09-08 13:23:00

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

LLY

Yahoo2026-09-08 13:00:00

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

WILMINGTON, Del., September 08, 2026--Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had not progressed following standard induction treatment w

AMGN

Benzinga2026-09-08 08:01:14

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.

BIDU

Yahoo2026-09-07 13:28:00

CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?

Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD.

CAPR

Yahoo2026-09-04 20:38:10

Stocks making big moves this week: SAIC, Reddit, Fortrea, GitLab, and G-III

Check out the companies making headlines this week:

SAIC

Yahoo2026-09-04 14:48:00

ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study

AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.

ABBV

Yahoo2026-09-04 14:37:00

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.

MRK

Yahoo2026-09-03 18:39:18

Stocks making big moves yesterday: Limbach, FuelCell Energy, Ollie's, Fortrea, and G-III

Check out the companies making headlines yesterday:

FCEL

Yahoo2026-09-03 14:41:05

AbbVie could take BiTE of Tecvayli market share on Phase III MM win

If approved, etentamig would join the increasingly competitive multiple myeloma market, which has seen the addition of several targeted therapies in recent years.

ABBV

Benzinga2026-09-03 09:54:53

Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday

U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake and other stocks rallied.

APPS

Yahoo2026-09-02 16:11:00

GSK to Advance mRNA Influenza Vaccine Into Phase III Development

GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.

ISRG

Yahoo2026-09-02 15:52:00

OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.

ISRG

Yahoo2026-09-02 13:10:01

G-III Apparel Group (GIII) Q2 Earnings Surpass Estimates

G-III Apparel (GIII) delivered earnings and revenue surprises of +4.00% and -2.86%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?

CTAS

Yahoo2026-08-18 15:46:00

MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain.

MESO

Yahoo2026-08-11 11:15:28

Tenax Therapeutics’ stock crashes on Phase III trial failure

Despite the miss, a subgroup of patients with more severe disease showed more meaningful benefit - data Tenax plans to submit to the FDA and EMA.

TENX

Yahoo2026-08-11 06:01:52

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics (NASDAQ:TENX) reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemody

TENX

SeekingAlpha2026-08-11 05:31:10

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients - Slideshow

2026-08-11. The following slide deck was published by Tenax Therapeutics, Inc.

TENX

SeekingAlpha2026-08-10 10:58:28

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

TENX

Yahoo

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growthPositive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer announced in July; FDA PDUFA action date of February 2027 with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decisionLitigation with GSK and Tesaro: trial held

Diagnostics

sourcesearch:archive

count20

archive_hits20

hintWorker/cron → market_news table for the default view; search spans the permanent news_archive plus a live Finnhub top-up